Evaluation of the Pattern of Thyroid Dysfunctions in Patients With Metabolic Syndrome
調査の概要
状態
詳細な説明
The metabolic syndrome (MetS) is a clustering of multiple risk factors for atherosclerotic cardiovascular disease such as central obesity, impaired fasting glucose (IFG) or type 2 diabetes mellitus (T2DM), elevated triglyceride (TG), reduced high density lipoprotein cholesterol (HDL-C) and hypertension (HTN).This cluster of metabolic abnormalities is associated with increased risk for atherosclerotic cardiovascular disease and type 2 diabetes mellitus Despite of the controversy on its definition, it is estimated that one out of four people around the world suffers from MetS. The prevalence of MetS is increasing all over the world.
Thyroid hormones play an important role in regulating energy homeostasis, carbohydrate, lipids and protein metabolism. These hormones accelerate metabolic processes and may be associated with metabolic syndrome. Hyperthyroidism is usually associated with low cholesterol and glucose intolerance; whereas hypothyroidism is associated with high cholesterol tendency, and patients are prone to weight gain and cardiac signs like bradycardia. Thyroid functions affect the components of MetS including HDLcholesterol (HDL-C), triglycerides (TG), blood pressure and plasma glucose.
Thyroid dysfunction (TD) is defined as the altered serum thyroid stimulating hormone (TSH) level with normal or altered thyroid hormones (free triiodothyronine and free thyroxine.TD is risk factors for CardioVascular Disease mediated by the effects of thyroid hormones on lipid and glucose metabolism and blood pressure, hence on components of MetS.MetS and TD are both characterized by a cluster of common abnormalities such as abdominal obesity, hyperglycemia, HTN, reduced HDL-C, and elevated TG and recognized independent risk factors of ASCVD ..Thyroid dysfunction, prominently subclinical hypothyroidism has been observed more frequently in metabolic syndrome patients than general population .
The study on evaluation the pattern of TD in MetS population may help us to know the magnitude of overlap of these two disease entities and may highlight the importance of thyroid function tests in patients with MetS. This can lead to proper planning and adequate management strategies, resulting in significant reduction in cardiovascular morbidity and mortality due to MetS with TD. Thus, this study aims to evaluate the pattern of TD in patients with MetS and to explore the relationship between TD and components of the MetS.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Assiut、エジプト
- Medicine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
Patients satisfying the 2005 Revised National Cholesterol Education Program/AdenosineTri Phosphate III which have three out of five of the following criteria:
- Central obesity - defined as waist circumference ≥102 cm for Men and ≥88cm for women.
- Raised triglycerides: ≥ 150 mg/dL, or specific treatment for this lipid abnormality.
- Reduced HDL cholesterol: < 40 mg/dL in males,< 50 mg/dL in females, or specific treatment for this lipid abnormality
- Raised blood pressure: systolic BP ≥130 or diastolic BP ≥85 mm Hg, or treatment of previously diagnosed hypertension.
Raised fasting plasma glucose :( FPG) ≥100 mg /dL, or previously diagnosed type 2 diabetes.
- knownly diagnosed diabetes mellitus .
- hypertension diagnosed patients .
- obese patients.
Exclusion Criteria: 1. Known hypothyroid or sub-clinical hypothyroid or hyperthyroid patients or on treatment.
2. Patients with liver disorders, renal disorders, congestive cardiac failure, pregnant women.
3. Patients with history of respiratory disease, malignancy, Smokers, alcoholics, 4. patients receiving medication that may alter thyroid functions or lipid levels,
-
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Thyroid stimulating hormone
時間枠:2 years.
|
Evaluation of thyroid dysfunctions in patients with metabolic syndrome
|
2 years.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Lipid profile
時間枠:2 years
|
To evaluate the associations between thyroid hormones levels and components of metabolic syndrome
|
2 years
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
メタボリック・シンドロームの臨床試験
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research Foundation; Cornelia... と他の協力者募集ミトコンドリア病 | 網膜色素変性症 | 重症筋無力症 | 好酸球性胃腸炎 | 多系統萎縮症 | 平滑筋肉腫 | 白質ジストロフィー | 痔瘻 | 脊髄小脳失調症3型 | フリードライヒ失調症 | ケネディ病 | ライム病 | 血球貪食性リンパ組織球症 | 脊髄小脳失調症1型 | 脊髄小脳性運動失調2型 | 脊髄小脳失調症6型 | ウィリアムズ症候群 | ヒルシュスプルング病 | 糖原病 | 川崎病 | 短腸症候群 | 低ホスファターゼ症 | レーバー先天性黒内障 | 口臭 | アカラシア心臓 | 多発性内分泌腫瘍 | リー症候群 | アジソン病 | 多発性内分泌腫瘍2型 | 強皮症 | 多発性内分泌腫瘍1型 | 多発性内分泌腫瘍2A型 | 多発性内分泌腫瘍2B型 | 非定型溶血性尿毒症症候群 | 胆道閉鎖症 | 痙性運動失調 | WAGR症候群 | アニリディア | 一過性全健忘症 | 馬尾症候群 | レフサム... およびその他の条件アメリカ, オーストラリア